TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reduction of maximal platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Timed Up and Go (TUG) - ON Usual Medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed Up and Go (TUG) - OFF Usual Medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-reported past-week worry
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in self-reported interpretation bias
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of transfusion events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in Total body water (TBW), extracellular water (ECW), intracellular water (ICW), and hydration status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in total energy expenditure (TEE), resting energy expenditure (REE), and physical activity energy expenditure (PAEE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in daily time spent in sedentary activities, light activities, moderate activities, and vigorous activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in Eczema Area and Severity Index (EASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Spine Cancer Outcomes Questionnaire (SCOQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ct values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage change in inflammatory acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in internal carotid artery (ICA) diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Phosphorus Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: muscle morphology of quadriceps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faecal levels of Bifidobacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Child percent overweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-tz for Digoxin, Metformin, Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-tz for Furosemide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for Furosemide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for Digoxin, Metformin, Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90 day continuous abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 7 day abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients who experience hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Carbon Monoxide-verified Continuous Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percentage of Donor Cells (Chimerism)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration of SC MNTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of missed pills per cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the study intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of the study intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of the study intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post-operative infective complications rate
Endpoint domain: Adverse events/effects
Primary endpoint: 6 months endoscopic recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Osteoarthritis Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Overall Health Status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: contracture size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in World Health Organization-5 (WHO-5)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Antiproteinuric effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: rate of lymphoceles requiring intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: disease specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: short-term pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short-term quality of life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevention of COVID-19 infection
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy of NORS at reducing progression of COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 12-lead ECG parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of antibody-mediated rejection (AMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Average AM Instantaneous Total Nasal Symptom Score (TNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average AM Instantaneous Total Ocular Symptom Score (TOSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to treatment based on baseline uPAR cleavage products
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile of Insulin Detemir
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Disease Control Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of persons with normal lipid values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dermatology Quality of Life Index (DQLI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percent of Subjects With an ICS POP-Q Stage of </= Stage I in the Posterior Compartment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percent of Subjects With an ICS POP-Q Stage of </= Stage I in the Apical Compartment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percent of Subjects With an ICS POP-Q Stage of </= Stage I in the Anterior Compartment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Participants Achieving 75% Improvement in PPPASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Difference in ET1 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in metabolomics profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macro-vascular reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Micro-vascular reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Investigator Global Assessment (IGA) Success Rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma concentration of Na+, K+, creatinin, osmolality at day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of number of nocturnal micturition episodes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Registration of number of side effects at day 3
Endpoint domain: Adverse events/effects
Primary endpoint: Area under curve of regional cerebral oxygen saturation (rSO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Artificial sweetener consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: minimum dose of phenylephrine preventing hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: minimum dose of phenylephrine preventing nausea/vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective surgeon feedback on surgical exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maladaptive fall risk appraisal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in GMFCS-FR Turkish Adaptation Reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SF-MPQ visual analog score (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weekly mean pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy measured by RECIST 1.1 criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: reduction in hepatic steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Global compliance of home-NIV
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in log10 CFU/mL of Direct Respiratory Sputum Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in physical function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PCR-corrected cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCORAD assessment of atopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Progression free survival (PFS) at 18 months
Endpoint domain: Mortality/survival
Primary endpoint: Vital bone formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Participants That Discontinued Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of patients with a correction of the INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Vaginal delivery rate within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Score on the Pressure Ulcer Scale for Healing (PUSH) Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: User Experience with the Dermatology Life Quality Index (DLQI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percent Change Per Day in Wound Surface Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change Per Day in Wound Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of clinically useful images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Serum Testosterone Cavg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With PASI 90 Response at Week 32
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in bone mineralisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Dental Fear Survey
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recanalization Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Sagittal stability of knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Area under the curve (AUC) with respect to changes of salivary cortisol titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of Testosterone Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Subjects With Plasmodium Falciparum Parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pain score (VAS) during activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brachial Artery Flow-mediated dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Range of Motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of Disabilities of the Arm, Shoulder and Hand (DASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: hand-writing speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival months
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity and specificity of MWR diagnostics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health status at 6 month follow up
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Health Care utilization at 6 month follow up
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Daily Mean Area Under The Effect-time Curve (AUEC) of dNCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Compliance with diabetes screening and preventive care guidelines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of In-stent restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma antiXa levels at peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Adverse Events of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Events that lead to permanent discontinuation of HUMIRA®
Endpoint domain: Adverse events/effects
Primary endpoint: postprandial blood glucose (iAUC) (0-240 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with increased number of IPCLs, dilatation or tortuosity of IPCLs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in cold and flu symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of radiodermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Wearing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients remaining alive
Endpoint domain: Mortality/survival
Primary endpoint: proportion of patients progression free
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pharmacokinetics of Vatalinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Flow Dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Physical activity energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent in physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Craving to Drink
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence rate of gastric cancer or high grade dysplasia
Endpoint domain: Mortality/survival
Primary endpoint: Facility 4 Antenatal Care (ANC) visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: mean LDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the concentration vs. time curve for serum concentration of montelukast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Pulmonary postoperative complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of fat layer in the abdominal area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Milk production volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Household milk yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Undernutrition (wasting, stunting and underweight)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biochemical Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants on the Ruxolitinib Arm Who Experienced Any Safety Milestone Events While On-Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Fold Change in the Level of Plasma Interleukin 6 (IL-6) From Baseline to Week 4/5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and tolerability of ZYD1
Endpoint domain: Adverse events/effects
Primary endpoint: cardiac ectopic fat deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: left myocardial regional function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with Adverse events (AE) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Anti-DNIB0600A Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to Recurrence of a Mood Episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anterior chamber angle parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Antibodies measured by 9-valent HPV competitive Luminex immunoassay (cLIA) (mMU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute allergic reaction (Grade 0 - 4)
Endpoint domain: Adverse events/effects
Primary endpoint: Injection site pain (Grade 0 - 4)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of children with low birthweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ciprofloxacin lung deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensitivity of AclarusDx™
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of relapse following discharge from the ED
Endpoint domain: Adverse events/effects
Primary endpoint: esthetic assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Student's satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Phos-p38 MAPK Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: p38 MAPK Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phospho-ERK MAPK Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ERK MAPK Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phospho-JNK MAPK Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: JNK MAPK Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall renal allograft survival
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of 50% or more in the eGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of abnormal GI findings per diagnostic procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Loss of body weight by more than 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in 6-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of steroid resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Assessment of physical examination findings
Endpoint domain: Adverse events/effects
Primary endpoint: Safety as assessed by 12-lead electrocardiogram (ECG)
Endpoint domain: Adverse events/effects
Primary endpoint: Myocardial Damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in NIH-CPSI total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in NIH-CPSI pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma GSK1349572 AUC(0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma GSK1349572 AUC(0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes